David Spencer Mangum
No Rating Available
(Learn About Our Rating System)

David Spencer Mangum, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

50 N Medical Dr
Salt Lake City , UT 84132
801-662-4700
Get Directions

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-587-4745
Get Directions

Dr. Mangum received his medical degree from the Albert Einstein College of Medicine (affiliated with Yeshiva University). He then completed his Pediatric residency at Primary Children´s Hospital (affiliated with the University of Utah), which was followed by a pediatric Hematology Oncology Fellowship at St Jude Children’s Research Hospital (affiliated with the University of Tennessee). Afterwards, he completed an additional two year Physician Scientist Training Program fellowship in the equivalent of an instructor role at St. Jude Children’s Research Hospital while still also continuing to care for patients. Following this, Dr. Mangum joined the faculty of Nemours Children’s Hospital in Delaware with an academic appointment as a clinical assistant professor of pediatrics at the Sidney Kimmel Medical College, where he practiced for three years. Dr. Mangum is currently an Assistant Professor of Pediatrics at the University of Utah and is in the Division of Pediatric Hematology Oncology. Dr. Mangum’s academic interests have focused primarily on Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, with his clinical interests focused on patients with Leukemias, Lymphomas, and histiocytic disorders of all kinds. However, he is comfortable with caring for any patient across the entire pediatric hematology oncology spectrum.

Specialties

Board Certification

American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
American Board of Pediatrics (Pediatrics)

Dr. Mangum received his medical degree from the Albert Einstein College of Medicine (affiliated with Yeshiva University). He then completed his Pediatric residency at Primary Children´s Hospital (affiliated with the University of Utah), which was followed by a pediatric Hematology Oncology Fellowship at St Jude Children’s Research Hospital (affiliated with the University of Tennessee). Afterwards, he completed an additional two year Physician Scientist Training Program fellowship in the equivalent of an instructor role at St. Jude Children’s Research Hospital while still also continuing to care for patients. Following this, Dr. Mangum joined the faculty of Nemours Children’s Hospital in Delaware with an academic appointment as a clinical assistant professor of pediatrics at the Sidney Kimmel Medical College, where he practiced for three years. Dr. Mangum is currently an Assistant Professor of Pediatrics at the University of Utah and is in the Division of Pediatric Hematology Oncology. Dr. Mangum’s academic interests have focused primarily on Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, with his clinical interests focused on patients with Leukemias, Lymphomas, and histiocytic disorders of all kinds. However, he is comfortable with caring for any patient across the entire pediatric hematology oncology spectrum.

Board Certification and Academic Information

Academic Departments Pediatrics -Associate Professor (Clinical)
Academic Divisions Hematology/Oncology
Board Certification
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
American Board of Pediatrics (Pediatrics)

Education history

Undergraduate Biomedical Engineering - University of Utah B.S.
Professional Medical Medicine - Albert Einstein College of Medicine of Yeshiva University M.D.
Residency General Pediatrics - University of Utah School of Medicine Resident
Fellowship Clinical Pediatric Hematology - Oncology - St. Jude Children's Research Hospital Fellow

Selected Publications

Journal Article

  1. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD (2021). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol, 7(10), 1521-1528.
  2. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Müschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan CG, Miles RR, Schiffman JD (2014). VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia, 28(1), 216-20.
  3. Mangum DS, Verma A, Weng C, Sheng X, Larsen R, Kirchhoff AC, Druzgal C, Fluchel M (2013). A comparison of central lines in pediatric oncology patients: Early removal and patient centered outcomes. Pediatr Blood Cancer, 60(11), 1890-5.
  4. Davidow K*, Mumanachit S*, Mangum D (2022). The two-hit hypothesis in practice: Monozygotic twins with simultaneous hyperdiploid acute lymphoblastic leukemia. Pediatric blood & cancer, 69(10), e29885.
  5. Mangum DS, Bishop JD, Zhou Y, Cheng C, Karol SE, Rubnitz JE, Ribeiro RC, Yang JJ, Mullighan CG, Jeha S, Pui CH, Inaba (2023). Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis. British journal of haematology, 200(3), 338-343.

Review

  1. Mangum DS, Caywood (2022). A clinician's guide to HLA matching in allogeneic hematopoietic stem cell transplant. Human immunology, 83(10), 687-694.

Case Report

  1. Parisio K*, Mangum DS, Powell J (2020). A novel and successful therapeutic approach in the treatment of a patient with simultaneous relapsed Ewing sarcoma and therapy-related acute myeloid leukemia. Pediatr Blood Cancer, 67(7), e28240.
  2. Ferguson-Paul K, Mangum S, Porter A, Leventaki V, Campbell P, Wolf J (2016). Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis. Emerg Infect Dis, 22(6), 1119-21.
  3. Kube P*, Parisio K*, Mangum DS, Powell (2022). Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity. BMJ case reports, 15(8),
  4. Gonzales MR*, White JC*, Mangum DS, Powell J (2022). Sporadic extranodal Rosai-Dorfman-Destombes disease treated with tocilizumab. Pediatric blood & cancer, e29754.